Meeting Overview | We are pleased to invite you to our satellite symposium, titled Multiple Myeloma: Targeting Improved Outcomes with Novel Strategies, to be held on 9 June 2011 at the 16th Congress of the European Hematology Association in London, United Kingdom. |
Date and Location | 9 June 2011
ExCel London
One Western Gateway
Royal Victoria Dock, London E16 1XL
United Kingdom
Hall S1 |
Target Audience | This educational activity is designed for hematologists, oncologists, and other healthcare professionals involved and/or interested in the management of patients with multiple myeloma and other hematologic malignancies. |
Learning Objectives | Upon completion of this educational activity, attendees should be able to:
- Describe the unique pathophysiology of myeloma, emphasizing how this impacts treatment decisions for multiple myeloma
- Compare and contrast induction therapy regimens for use in newly diagnosed patients with multiple myeloma
- Discuss the rationale for using bone-targeted therapies in combination with other treatment modalities for the management of multiple myeloma
- Analyze clinical trial data regarding emerging options for maintenance therapy in myeloma
- Evaluate treatment options for patients with relapsed/refractory multiple myeloma, with an emphasis on the need for individualization of therapy
|
 Faculty | Chair
Evangelos Terpos, MD, PhD
University of Athens
Athens, Greece
|
Faculty
Mario Boccadoro, MD
Ospedale San Giovanni
Torino, Italy
|
Faith Davies, MD
Royal Marsden Hospital
Sutton, United Kingdom
|
Michel Delforge, MD, PhD
University Hospital Leuven
Leuven, Belgium
|
Andreas Günther, MD
University of Kiel
Kiel, Germany
|
|
Agenda |
| 10.45 |
|
Welcome and introduction
Evangelos Terpos, MD, PhD
|
| 10.50 |
|
Pathophysiology of myeloma
Evangelos Terpos, MD, PhD
|
| 11.10 |
|
Current therapeutic approaches in management of a newly diagnosed multiple myeloma patient
Mario Boccadoro, MD
|
| 11.30 |
|
Bone-targeted therapy: An important adjunct to current myeloma therapy
Faith Davies, MD
|
| 11.50 |
|
Emerging concepts in maintenance therapy
Michel Delforge, MD, PhD
|
| 12.10 |
|
Advances in relapsed/refractory multiple myeloma
Andreas Günther, MD
|
| 12.30 |
|
Expert commentary and discussion
All Faculty
|
| 12.45 |
|
Concluding remarks
Evangelos Terpos, MD, PhD
|
|
|
|
|
Continuing Professional Development | This activity has been approved for 2 External credits by the Federation of the Royal College of Physicians (UK). Delegates are reminded that a maximum of six External CPD points may be counted for educational activity on any one day. RCP Activity Code #: 64445. |
Support | Support for this activity has been provided by Celgene Corporation and Novartis Oncology
 |
Organizer | This meeting is a prIME Oncology activity.
 |
|
